Completed
PHASE1
INTERVENTIONAL
NCT02212067
A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This trial is conducted in Europe. The aim of the trial is to investigate the effects of semaglutide on ß-cell function in subjects with type 2 diabetes.
Interventions
Name:
semaglutide
Type:
DRUG
Description:
Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
Name:
placebo
Type:
DRUG
Description:
Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
Primary Outcomes
Measure:
Area under the serum insulin concentration time curve from 0 to 10 minutes after a 25 g glucose bolus i.v. infusion (IVGTT,intravenous glucose tolerance test) over 2 minutes
TimeFrame:
Day -1, day 86
Description:
Measure:
Area under the serum insulin concentration time curve from 10-120 minutes after a 25 g glucose bolus i.v. infusion (IVGTT).
TimeFrame:
Day -1, day 86
Description:
Trial Information
NCT ID
NCT02212067
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025